200 related articles for article (PubMed ID: 32814714)
1. Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target.
Pierini S; Tanyi JL; Simpkins F; George E; Uribe-Herranz M; Drapkin R; Burger R; Morgan MA; Facciabene A
JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32814714
[TBL] [Abstract][Full Text] [Related]
2. Aberrant granulosa cell-fate related to inactivated p53/Rb signaling contributes to granulosa cell tumors and to FOXL2 downregulation in the mouse ovary.
Cluzet V; Devillers MM; Petit F; Chauvin S; François CM; Giton F; Genestie C; di Clemente N; Cohen-Tannoudji J; Guigon CJ
Oncogene; 2020 Feb; 39(9):1875-1890. PubMed ID: 31745296
[TBL] [Abstract][Full Text] [Related]
3. A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors.
Tobias J; Battin C; De Sousa Linhares A; Lebens M; Baier K; Ambroz K; Drinić M; Högler S; Inic-Kanada A; Garner-Spitzer E; Preusser M; Kenner L; Kundi M; Zielinski CC; Steinberger P; Wiedermann U
Front Immunol; 2020; 11():895. PubMed ID: 32528470
[TBL] [Abstract][Full Text] [Related]
4. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial.
How JA; Jazaeri A; Westin SN; Sood AK; Ramondetta LM; Xu M; Abonofal A; Karp DD; Subbiah V; Stephen B; Rodon JA; Yang F; Naing A
Invest New Drugs; 2021 Jun; 39(3):829-835. PubMed ID: 33415580
[TBL] [Abstract][Full Text] [Related]
5. Impact of FOXL2 mutations on signaling in ovarian granulosa cell tumors.
Leung DTH; Fuller PJ; Chu S
Int J Biochem Cell Biol; 2016 Mar; 72():51-54. PubMed ID: 26791928
[TBL] [Abstract][Full Text] [Related]
6. Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease.
Pilsworth JA; Cochrane DR; Neilson SJ; Moussavi BH; Lai D; Munzur AD; Senz J; Wang YK; Zareian S; Bashashati A; Wong A; Keul J; Staebler A; van Meurs HS; Horlings HM; Kommoss S; Kommoss F; Oliva E; Färkkilä AE; Gilks B; Huntsman DG
J Pathol Clin Res; 2021 May; 7(3):243-252. PubMed ID: 33428330
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
[TBL] [Abstract][Full Text] [Related]
8. Estrogen regulates forkhead transcription factor 2 to promote apoptosis of human ovarian granulosa-like tumor cells.
Wu J; Miao C; Lv X; Zhang Y; Li Y; Wang D
J Steroid Biochem Mol Biol; 2019 Nov; 194():105418. PubMed ID: 31376461
[TBL] [Abstract][Full Text] [Related]
9. FOXL2, GATA4, and SMAD3 co-operatively modulate gene expression, cell viability and apoptosis in ovarian granulosa cell tumor cells.
Anttonen M; Pihlajoki M; Andersson N; Georges A; L'hôte D; Vattulainen S; Färkkilä A; Unkila-Kallio L; Veitia RA; Heikinheimo M
PLoS One; 2014; 9(1):e85545. PubMed ID: 24416423
[TBL] [Abstract][Full Text] [Related]
10. Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression.
Pierini S; Mishra A; Perales-Linares R; Uribe-Herranz M; Beghi S; Giglio A; Pustylnikov S; Costabile F; Rafail S; Amici A; Facciponte JG; Koumenis C; Facciabene A
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563772
[TBL] [Abstract][Full Text] [Related]
11. FOXL2 Mutation Status in Granulosa Theca Cell Tumors of the Ovary.
Nolan A; Joseph NM; Sangoi AR; Rabban J; Zaloudek C; Garg K
Int J Gynecol Pathol; 2017 Nov; 36(6):568-574. PubMed ID: 28319575
[TBL] [Abstract][Full Text] [Related]
12. FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring.
Groeneweg JW; Roze JF; Peters EDJ; Sereno F; Brink AGJ; Paijens ST; Nijman HW; van Meurs HS; van Lonkhuijzen LRCW; Piek JMJ; Lok CAR; Monroe GR; van Haaften GW; Zweemer RP
Gynecol Oncol; 2021 Aug; 162(2):413-420. PubMed ID: 34083028
[TBL] [Abstract][Full Text] [Related]
13. Aromatase is a direct target of FOXL2: C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter.
Fleming NI; Knower KC; Lazarus KA; Fuller PJ; Simpson ER; Clyne CD
PLoS One; 2010 Dec; 5(12):e14389. PubMed ID: 21188138
[TBL] [Abstract][Full Text] [Related]
14. Mutant FOXL2
Weis-Banke SE; Lerdrup M; Kleine-Kohlbrecher D; Mohammad F; Sidoli S; Jensen ON; Yanase T; Nakamura T; Iwase A; Stylianou A; Abu-Rustum NR; Aghajanian C; Soslow R; Da Cruz Paula A; Koche RP; Weigelt B; Christensen J; Helin K; Cloos PAC
Cancer Res; 2020 Sep; 80(17):3466-3479. PubMed ID: 32641411
[TBL] [Abstract][Full Text] [Related]
15. FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines.
Kommoss S; Anglesio MS; Mackenzie R; Yang W; Senz J; Ho J; Bell L; Lee S; Lorette J; Huntsman DG; Blake Gilks C
Mod Pathol; 2013 Jun; 26(6):860-7. PubMed ID: 23348906
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary.
Färkkilä A; Haltia UM; Tapper J; McConechy MK; Huntsman DG; Heikinheimo M
Ann Med; 2017 Aug; 49(5):435-447. PubMed ID: 28276867
[TBL] [Abstract][Full Text] [Related]
17. FOXL2 Mutation Status in Sex Cord-stromal Tumors Cannot be Predicted by Morphology.
Wessman S; Fuentes BB; Severin-Karlsson J; Westbom-Fremer S; Nistér M; Kokaraki G; Petta TB; Haglund F; Carlson JW
Int J Gynecol Pathol; 2024 Jan; 43(1):78-89. PubMed ID: 37255476
[TBL] [Abstract][Full Text] [Related]
18. Absence of a FOXL2 mutation (402C→G) in the blood of adult-type granulosa cell tumor patients possessing the FOXL2 mutation.
Lee S; Kim TH; Won M; Ko JJ; Rho J; Lee K; Bae J
Int J Gynecol Cancer; 2010 Nov; 20(8):1341-3. PubMed ID: 21051974
[TBL] [Abstract][Full Text] [Related]
19. DICER1 and FOXL2 mutations in ovarian sex cord-stromal tumours: a GINECO Group study.
Goulvent T; Ray-Coquard I; Borel S; Haddad V; Devouassoux-Shisheboran M; Vacher-Lavenu MC; Pujade-Laurraine E; Savina A; Maillet D; Gillet G; Treilleux I; Rimokh R
Histopathology; 2016 Jan; 68(2):279-85. PubMed ID: 26033501
[TBL] [Abstract][Full Text] [Related]
20. DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor.
Wang C; Zainal NS; Chai SJ; Dickie J; Gan CP; Zulaziz N; Lye BKW; Sutavani RV; Ottensmeier CH; King EV; Abraham MT; Ismail SMB; Lau SH; Kallarakkal TG; Mun KS; Zain RB; Abdul Rahman ZA; Thomas GJ; Cheong SC; Savelyeva N; Lim KP
Front Immunol; 2021; 12():763086. PubMed ID: 34733290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
